Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ovation Science ( (TSE:OVAT) ) just unveiled an announcement.
Ovation Science has secured a new Canadian patent for its proprietary topical formulations containing CBD and THC, extending protection for its transdermal delivery technology beyond its existing U.S. patent and strengthening its international intellectual property portfolio. With patents now in both the U.S. and Canada, the company is better positioned to pursue exclusive licensing deals, strategic partnerships and premium product placement in two of the largest regulated cannabis markets, supporting recurring licensing revenue and long-term growth. The newly protected formulations, powered by Ovation’s Invisicare technology, have demonstrated significantly higher cannabinoid bioavailability compared with competing topical and oral products, reinforcing Ovation’s differentiated performance claims and making its platform more attractive to licensees across cannabis, wellness, pharmaceutical and beauty categories as regulatory frameworks evolve.
The most recent analyst rating on (TSE:OVAT) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Ovation Science stock, see the TSE:OVAT Stock Forecast page.
Spark’s Take on TSE:OVAT Stock
According to Spark, TipRanks’ AI Analyst, TSE:OVAT is a Neutral.
The score is primarily constrained by weak financial performance (ongoing losses, negative equity, and cash burn). Technical indicators add modest pressure with negative MACD and sub-50 RSI, while valuation remains unattractive due to loss-making status and no dividend support.
To see Spark’s full report on TSE:OVAT stock, click here.
More about Ovation Science
Ovation Science Inc., based in Vancouver and Las Vegas, is a research and development company specializing in topical and transdermal cannabinoid products incorporating CBD, THC and other cannabinoids. It generates revenue primarily by out-licensing its proprietary formulations and Invisicare drug-delivery technology to licensed operators by state or country, while also marketing its own CBD-based ARLO Beauty and InVibe MD wellness brands aimed at medical, wellness and anti-aging/beauty segments.
Average Trading Volume: 41,449
Technical Sentiment Signal: Sell
Current Market Cap: C$1.41M
Learn more about OVAT stock on TipRanks’ Stock Analysis page.